Difference between revisions of "Daratumumab (Darzalex)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
=Mechanism of action= | =Mechanism of action= | ||
| − | + | From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=583564 NCI Drug Dictionary]: A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of daratumumab to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). | |
=Preliminary data= | =Preliminary data= | ||
Revision as of 14:19, 18 September 2015
Mechanism of action
From the NCI Drug Dictionary: A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of daratumumab to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Preliminary data
Multiple myeloma
- Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Aug 26. [Epub ahead of print] link to original article PubMed